247 related articles for article (PubMed ID: 38162126)
1. Thrombopoietin-receptor agonists for adult patients with immune thrombocytopenia: a narrative review and an approach for managing patients fasting intermittently.
Yassin MA; Al-Rasheed M; Al-Khaboori M; Marashi M; Osman H; Wali Y; Al Kindi S; Alsayegh F; Provan D
Front Cardiovasc Med; 2023; 10():1260487. PubMed ID: 38162126
[TBL] [Abstract][Full Text] [Related]
2. An updated evaluation of avatrombopag for the treatment of chronic immune thrombocytopenia.
Song AB; Al-Samkari H
Expert Rev Clin Immunol; 2022 Aug; 18(8):783-791. PubMed ID: 35793401
[TBL] [Abstract][Full Text] [Related]
3. Adults with immune thrombocytopenia who switched to avatrombopag following prior treatment with eltrombopag or romiplostim: A multicentre US study.
Al-Samkari H; Jiang D; Gernsheimer T; Liebman H; Lee S; Wojdyla M; Vredenburg M; Cuker A
Br J Haematol; 2022 May; 197(3):359-366. PubMed ID: 35179784
[TBL] [Abstract][Full Text] [Related]
4. Thrombopoietin Receptor Agonists (TPO-RAs): Drug Class Considerations for Pharmacists.
Gilreath J; Lo M; Bubalo J
Drugs; 2021 Jul; 81(11):1285-1305. PubMed ID: 34160821
[TBL] [Abstract][Full Text] [Related]
5. Use of thrombopoietin receptor agonists in adults with immune thrombocytopenia: a systematic review and Central European expert consensus.
Pulanić D; Bátorová A; Bodó I; Červinek L; Ionita I; Lissitchkov T; Melikyan A; Podolak-Dawidziak M
Ann Hematol; 2023 Apr; 102(4):715-727. PubMed ID: 36826482
[TBL] [Abstract][Full Text] [Related]
6. Thrombopoietin receptor agonist for treatment of immune thrombocytopenia in pregnancy: a narrative review.
Agarwal N; Mangla A
Ther Adv Hematol; 2021; 12():20406207211001139. PubMed ID: 33796239
[TBL] [Abstract][Full Text] [Related]
7. The structure, function, and clinical use of the thrombopoietin receptor agonist avatrombopag.
Kuter DJ
Blood Rev; 2022 May; 53():100909. PubMed ID: 34815110
[TBL] [Abstract][Full Text] [Related]
8. An evaluation of avatrombopag for the treatment of thrombocytopenia.
Virk ZM; Kuter DJ; Al-Samkari H
Expert Opin Pharmacother; 2021 Feb; 22(3):273-280. PubMed ID: 33095074
[No Abstract] [Full Text] [Related]
9. Thrombopoietin level predicts response to treatment with eltrombopag and romiplostim in immune thrombocytopenia.
Al-Samkari H; Kuter DJ
Am J Hematol; 2018 Dec; 93(12):1501-1508. PubMed ID: 30187942
[TBL] [Abstract][Full Text] [Related]
10. European Delphi panel to build consensus on tapering and discontinuing thrombopoietin receptor agonists in immune thrombocytopenia.
Barlassina A; González-López TJ; Cooper N; Zaja F
Platelets; 2023 Dec; 34(1):2170999. PubMed ID: 36803535
[TBL] [Abstract][Full Text] [Related]
11. Optimal use of thrombopoietin receptor agonists in immune thrombocytopenia.
Al-Samkari H; Kuter DJ
Ther Adv Hematol; 2019; 10():2040620719841735. PubMed ID: 31007886
[TBL] [Abstract][Full Text] [Related]
12. Thrombopoietin receptor agonists for prevention and treatment of chemotherapy-induced thrombocytopenia in patients with solid tumours.
Zhang X; Chuai Y; Nie W; Wang A; Dai G
Cochrane Database Syst Rev; 2017 Nov; 11(11):CD012035. PubMed ID: 29178132
[TBL] [Abstract][Full Text] [Related]
13. Thrombopoietin mimetics for patients with myelodysplastic syndromes.
Dodillet H; Kreuzer KA; Monsef I; Skoetz N
Cochrane Database Syst Rev; 2017 Sep; 9(9):CD009883. PubMed ID: 28962071
[TBL] [Abstract][Full Text] [Related]
14. Budget impact analysis for avatrombopag in the treatment of chronic primary immune thrombocytopenia in adult patients refractory to other treatments.
Aiello A; Mariano EE; Prada M; Teruzzi C; Martone N; Capri S; Carli G; Siragusa S
J Mark Access Health Policy; 2023; 11(1):2230663. PubMed ID: 37405228
[No Abstract] [Full Text] [Related]
15. Comparative Efficacy and Safety of Thrombopoietin Receptor Agonists in Adults With Thrombocytopenia: A Systematic Review and Network Meta-analysis of Randomized Controlled Trial.
Deng J; Hu H; Huang F; Huang C; Huang Q; Wang L; Wu A; Yang J; Qin D; Zou W; Wu J
Front Pharmacol; 2021; 12():704093. PubMed ID: 34393785
[TBL] [Abstract][Full Text] [Related]
16. Switching thrombopoietin receptor agonist treatments in patients with primary immune thrombocytopenia.
González-Porras JR; Godeau B; Carpenedo M
Ther Adv Hematol; 2019; 10():2040620719837906. PubMed ID: 31156798
[TBL] [Abstract][Full Text] [Related]
17. Role of thrombopoietin receptor agonists in chemotherapy-induced thrombocytopenia: A meta-analysis.
Gurumurthy G; Kisiel F; Gurumurthy S; Gurumurthy J
J Oncol Pharm Pract; 2023 Dec; ():10781552231219003. PubMed ID: 38155484
[TBL] [Abstract][Full Text] [Related]
18. Eltrombopag modulates the phenotypic evolution and potential immunomodulatory roles of monocytes/macrophages in immune thrombocytopenia.
Yang F; Zong H; Li F; Luo S; Zhang X; Xu Y; Zhang X
Platelets; 2023 Dec; 34(1):2135694. PubMed ID: 36281771
[TBL] [Abstract][Full Text] [Related]
19. Clinical overview and practical considerations for optimizing romiplostim therapy in patients with immune thrombocytopenia.
Kuter DJ; Tarantino MD; Lawrence T
Blood Rev; 2021 Sep; 49():100811. PubMed ID: 33781612
[TBL] [Abstract][Full Text] [Related]
20. Avatrombopag for the Treatment of Adult Patients with Chronic Immune Thrombocytopenia (cITP): Focus on Patient Selection and Perspectives.
Tsykunova G; Ghanima W
Ther Clin Risk Manag; 2022; 18():273-286. PubMed ID: 35386180
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
